New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.
You may also be interested in...
Merck & Co will start late-stage CMV prevention testing of first-in-class viral terminase complex inhibitor in renal transplant patients during the first half of 2018, following its launch for stem cell transplant recipients.
The latest drug approval and development news from our US FDA Performance Tracker.
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.